37 results about "New diagnosis" patented technology

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention discloses application of HOXD1 in diagnosis, prognosis and treatment of liver cancer, and particularly relates to application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for diagnosing a liver cancer object. The invention discloses application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for prognosis of a liver cancer object. The invention discloses an application of HOXD1 as a target in screening medicines for treating liver cancer. The HOXD1 expression inhibitor is applied to preparation of a medicine for treating liver cancer. Differential expression of the HOXD1 in hepatocellular carcinoma tissues and normal hepatocellular carcinoma tissues is clear through research, high expression of the HOXD1 is closely related to the survival reduction period of clinical hepatocellular carcinoma patients, specific knock-down of the HOXD1 can obviously reduce the proliferation capacity of the hepatocellular carcinoma, and a new diagnosis / prognosis marker and a treatment target are provided for early discovery, early treatment and prognosis of the hepatocellular carcinoma. And a new treatment strategy and direction are provided.

The invention provides a spinal health monitoring method and system combining remote sensing three-dimensional modeling and AI pre-diagnosis. The method comprises the following steps: (1) constructing a rapid three-dimensional reconstruction module based on flow diffusion: realizing high-fidelity three-dimensional modeling by adopting a lightweight shape generation and intelligent texture mapping technology; (2) intelligent grading evaluation of scoliosis driven by a large model: based on a large-scale spine feature data set, constructing a deep learning network for automatic measurement and typing prediction of spine parameters, and deeply fusing the deep learning network with a semantic understanding module of an AI intelligent question-answering system; and (3) doctor-worker collaborative diagnosis and feedback optimization: doctors can view the user model and the AI evaluation report and make new diagnosis, meanwhile, the system utilizes natural language processing to extract doctor diagnosis keywords, and the model is continuously optimized based on parameter transfer learning. According to the invention, the whole-process Web deployment of spine detection is realized, a medical vertical domain large model for spine detection is developed, and the extensible technical framework has huge application potential in the field of intelligent medical treatment.

The invention provides application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract, and belongs to the technical field of medicines. The invention discloses application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract. Results of the invention show that the D-pyroglutamic acid can effectively inhibit aggregation of crystalline lens proteins. In addition, the D-pyroglutamic acid drug is low in cytotoxicity, directly acts on crystalline epithelial cells and can effectively inhibit damage to the crystalline epithelial cells. Therefore, the medical application of the D-pyroglutamic acid is expanded, and meanwhile, a new diagnosis and treatment strategy is provided for attack and prevention of cataract.

The invention relates to the technical field of image analysis, in particular to a breast cancer screening analysis system and method based on multi-modal image fusion, and the system comprises an information entropy weight adjustment module, a time-frequency domain feature processing module, a geometric correction fusion module, a data real-time updating module and a comprehensive analysis output module. According to the method, weight distribution is optimized by evaluating the contribution degree of each mode in a specific scene, the data processing accuracy in the diagnosis process is enhanced, time-frequency domain conversion and filtering synchronization are carried out on image data, efficient integration of different mode features is achieved, and image alignment is more accurate through multi-scale decomposition and feature matching of geometric correction; the method has the advantages of reducing the misdiagnosis rate, flexibly adjusting and keeping the timeliness and adaptability of a processing strategy according to new diagnosis data, and remarkably improving the accuracy of early detection of breast cancer by strengthening key diagnosis features and improving the expression quality of image data, thereby playing a positive role in improving the survival rate and life quality of patients.

The invention belongs to the technical field of biomedicine, and particularly relates to a nucleic acid combination product for detecting SIAH2, a diagnostic kit for osteoarthritis and application of the diagnostic kit. According to the application, the models are established by using machine learning to analyze various cell death modes, and the application finds that in the models of the four cell death modes, the ferroptosis model has the highest diagnosis efficiency on the OA and identifies the corresponding biomarkers. It is found that SIAH2 is used as a biomarker to regulate occurrence and development of OA through cartilage cells, and a new diagnosis and treatment strategy is provided for OA.

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

The invention discloses an electrical design and debugging integrated intelligent platform and an implementation method. Comprising the steps of setting a data model of electrical design debugging; the method comprises the following steps: mapping design data generated based on an electrical logic diagram before debugging to obtain initial debugging data; the simulation model and the physical equipment are connected, a semi-physical simulation environment is constructed, variables of the simulation model and physical signals of the physical equipment are fused during debugging, and debugging data are obtained and updated; performing inverse mapping on the updated debugging data to obtain updated design data, and obtaining an updated electrical logic diagram based on the updated data; and based on the diagnosis knowledge in the data model library, an intelligent diagnosis module is adopted to diagnose the debugging data updated during debugging to obtain new diagnosis data. Design and debugging integration of electrical development is realized, and the intelligent level of fault diagnosis is improved.

The invention belongs to the field of circuit protection, and provides an overcurrent protection monitoring method and system for a frequency converter. The method comprises the following steps: continuously acquiring current time sequence data of three-phase current of each frequency converter in a workstation, sampling to form an original data set, and standardizing the original data set; fault segmentation is carried out on the standardized original data set, so that abnormal data and normal data in the original data set are separated; converting an original data set representing abnormal data from a time domain to a frequency domain based on discrete Fourier transform to obtain a new diagnosis data set; based on a principal component analysis technology, features in the diagnosis data set are extracted and dimensionally reduced to obtain a feature set, the square prediction error of each feature in the feature set is calculated, the total contribution degree of the features is obtained according to the influence of the square prediction error on other features, and whether a detected object fails or not is determined; therefore, the problem that in the prior art, irregular overcurrent faults which do not reach the threshold value are difficult to diagnose can be solved.

The invention belongs to the technical field of biological medicines, and discloses application of L-lactic acid in preparation of a medicine for promoting muscle injury repair and / or regeneration. The L-lactic acid can significantly promote proliferation and differentiation of muscle satellite cells, and helps to improve some external stimulation factors, such as myasthenia, amyotrophy, poor muscle coordination and other skeletal muscle dysfunction diseases caused by aging, injury, disuse or some degenerative diseases, such as poor prognosis. The invention provides a new diagnosis and treatment strategy and an effective molecular treatment target for treatment and prognosis of skeletal muscle dysfunction diseases. And on the other hand, the L-lactic acid provided by the invention is a small molecule metabolite, is relatively low in economic cost and relatively good in treatment effect, and has a considerable clinical application prospect.

The present invention discloses an application of C21orf58 in the preparation of liver cancer diagnosis and / or prognosis, and treatment preparations, and a diagnosis, prognosis, and treatment preparation. The present invention first discovered that C21orf58 is closely related to the diagnosis, prognosis, and clinical drug resistance treatment of liver cancer, and is a key gene for the occurrence and development of tumors. Patients with low expression of the C21orf58 gene have a higher survival rate. Therefore, compared with the prior art, the new liver cancer diagnosis and treatment scheme using the C21orf58 gene as a molecular marker has strong clinical application value and potential.

The invention discloses a diagnostic marker for the drug resistance of kidney cancer sunitinib. The diagnostic marker for the drug resistance of kidney cancer sunitinib is selected from a group consisting of histone acetyltransferase KAT2A. The invention further discloses a kit for detecting the sunitinib drug resistance of the kidney cancer. The kit comprises a reagent for detecting the expression quantity of KAT2A. The KAT2A provided by the invention is used as a renal cancer sunitinib drug resistance diagnosis marker, has good specificity and high sensitivity, provides a new diagnosis and treatment means for renal cancer sunitinib drug resistance, is beneficial to drug resistance monitoring and avoids further invalid treatment, and has a good medical conversion prospect.

The invention discloses a gene group for breast cancer molecular typing, a detection product and application of the gene group and the detection product, and relates to the technical field of breast cancer tumor gene detection. Comprising the following steps: S1, collecting clinical tissue specimens, including cancer tissues and para-carcinoma tissues, coming from breast cancer patients receiving breast resection, and storing the tissue specimens in liquid nitrogen; s2, cell culture: culturing a breast cancer cell line by using a DMEM culture medium containing 10% of fetal calf serum; the relation between high expression of circACTN4 in breast cancer and clinical pathological characteristics of circACTN4 is proved through multiple methods such as gene chip analysis, qRT-PCR, cell function experiments and animal experiments, and circACTN4 promotes acetylation of histone H4 and increases expression of cell cycle related genes (such as CCNE1 and CDK4) by up-regulating expression of MYC, so that development of breast cancer is promoted; a new molecular marker and a potential treatment target are provided for diagnosis and treatment of breast cancer, and development of new diagnosis products and treatment strategies is facilitated.

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The invention provides an application of a novel biomarker CD36 of acute kidney injury caused by sepsis (SAKI) in the detection, diagnosis and treatment of the SAKI, and provides an application of the novel biomarker CD36 of the acute kidney injury caused by the sepsis (SAKI) in the detection, diagnosis and treatment of the SAKI. According to the invention, bioinformatics analysis and exploration are utilized to confirm that kidney CD36 and SAKI have good correlation in people, and animal models are also verified, so that a new diagnosis and treatment marker is provided for clinical diagnosis and treatment of SAKI, and the application has important clinical significance.

The invention belongs to the technical field of biomedicine, and particularly relates to application of a BIRC5 gene in prediction of drug resistance in bladder cancer immunotherapy and in depletion of immune subtypes. The invention is achieved by detecting the expression level of the BIRC5 gene in a tumor sample from a bladder cancer patient, where high expression of BIRC5 indicates that the patient belongs to the depleted immune subtype and predicts drug resistance to immune checkpoint blocking (ICB) treatment. In addition, the invention also discloses an application of the BIRC5 gene as a target spot in screening drugs for reversing tumor immunosuppression microenvironment in bladder cancer or overcoming immunotherapy drug resistance. The invention provides a new biomarker and a therapeutic target for a new depletion immune subtype of bladder cancer, and provides a new diagnosis and treatment strategy for immunotherapy of drug-resistant bladder cancer patients.

Embodiments herein describe an automated notification system that can detect a change to a person's medical record, notify an authorized person (e.g., a family member), and direct the authorized person to a health portal to view the change. The health portal then authenticates the person to ensure they are authorized to access the health record. Once authenticated, the health portal displays a graphical user interface (GUI) that includes both the older information in the medical record as well as the change in the record (e.g., a new diagnosis or new medication). The GUI can use a visual indicator to emphasize the change to the medical record to easily distinguish it from the older information (e.g., previous diagnosis and medications).

Various embodiments of the present invention provide methods, apparatus, systems, computing devices, computing entities, and / or the like for generating a historically dynamic explanation data object for a dental image data object. Certain embodiments of the present invention utilize systems, methods, and computer program products that perform generating a historically dynamic explanation data object for a dental image data object using an encoder-decoder architecture, where the encoder machine learning framework of the encoder-decoder architecture comprises a current diagnosis identification machine learning model, a historical diagnosis identification machine learning model, a convolutional embedding machine learning model, a new diagnosis code inference machine learning model, and a feature vector combination machine learning model.

The invention discloses an oligosaccharide chain fingerprint spectrum prediction model for identifying staphylococcus epidermidis infection and a construction method and application thereof, and belongs to the technical field of molecular biomedicine. The invention discovers that active infection of staphylococcus epidermidis can cause glycoprotein in host serum to generate a characteristic oligosaccharide chain fingerprint spectrum for the first time, and the spectrum can be used as a specific biomarker. Based on the discovery, the invention provides a construction method of a prediction model, which comprises the following steps: acquiring oligosaccharide chain atlas data of a serum sample, training by utilizing a machine learning algorithm, constructing a classifier capable of outputting an infection state prediction value, and determining a judgment threshold for distinguishing infection and negative. By applying the model, the active infection of the staphylococcus epidermidis can be quickly and accurately identified, and sample pollution can be effectively distinguished. The invention provides a brand new diagnosis solution for clinical application, and has important clinical application value.

The application discloses an oncogene VGLL1 and application of a protein coded by the oncogene VGLL1, and particularly discloses application of a VGLL1 gene and / or a coded protein thereof in preparation of a medicine for treating cancer, and application of the VGLL1 gene and / or the coded protein thereof in preparation of a reagent or a kit for cancer diagnosis and / or prognosis judgment. It is found in the application that the oncogene VGLL1 has an important role in the occurrence and development process of tumors, and high expression of VGLL1 can induce malignant progression such as invasion and metastasis of ovarian cancer. It is also found in the research result that conditionally down-regulating VGLL1 can effectively relieve the growth of ovarian cancer cells and inhibit the invasion and metastasis ability of the ovarian cancer cells. The application provides a new diagnosis and treatment idea and a drug screening platform for solving clinical problems such as metastasis of ovarian cancer.

The invention discloses a quality control feedback method and system for electrocardio data and diagnosis results, and the quality control feedback method for the electrocardio data and the diagnosis results comprises three steps. The method has remarkable advantages in the aspect of automatically feeding back and updating the electrocardiogram database, and due to the fact that an existing system mostly depends on manual database maintenance, the updating period is long, response is lagged, newest clinical diagnosis characteristics are difficult to reflect in time, and an effective quality control mechanism is lacked in the data storage process. According to the method, dynamic self-optimization and updating of the database can be realized. According to the method, text analysis and key content extraction are performed on a clinical diagnosis result of an electrocardiogram by using a deep learning model, and similarity matching is performed by combining electrocardiogram characteristics of an object with existing data in a database. And if the matching degree is lower than a set threshold value, the new diagnosis and the features thereof are automatically put in storage, so that real-time learning and continuous expansion are realized. The local database has the adaptive learning capability, and the intelligence and data timeliness of the system are remarkably improved.

The invention discloses application of leucine aminopeptidase in preparation of a product for diagnosing atherosclerosis or evaluating atherosclerotic plaque vulnerability, and discloses direct association between LAP and AS plaque vulnerability and application of LAP as a cardiovascular and cerebrovascular disease diagnosis biomarker for the first time. The invention relates to application of the LAP activity in preparation of a product for diagnosing AS or evaluating AS plaque vulnerability, further provides a first method for in-vivo, real-time and dynamic visual imaging of the LAP activity in a living body AS plaque, in addition, the feasibility of diagnosing AS based on the LAP activity is verified in various human source clinical samples for the first time, the perfect distinction degree is achieved, and finally, the application of the LAP activity in preparation of a product for diagnosing AS or evaluating AS plaque vulnerability is achieved. A complete evidence chain is formed through multi-modal means such as in-vivo imaging, in-vitro imaging and histopathology; the method has the advantages that a brand new diagnosis and research direction is opened up for AS diagnosis or AS plaque vulnerability evaluation, the LAP activity in the AS plaque can be specifically identified and imaged and displayed in a living body environment, and a more accurate and timely disease monitoring means is provided.

The invention provides application of a novel biomarker sKLB of sepsis intestinal mucous barrier damage in detection, diagnosis and treatment of sepsis. Clinical sample exploration proves that the sKLB has good correlation with sepsis in people, so that a new diagnosis and treatment marker is provided for clinical diagnosis and treatment of sepsis, and the application has important clinical significance.

The invention belongs to the technical field of diabetes diagnosis, and particularly relates to application of a reagent for detecting intestinal microorganisms and excrement metabolites in preparation of a preparation for diagnosing diabetes and a kit. Key biomarkers including key differential intestinal microorganisms and key differential fecal metabolites are screened through metagenomics and metabonomics, and the clinical value of the key biomarkers lies in that a multi-omics classifier for distinguishing adult illness T1D from healthy people (HC) and T2D is finally determined. The kit is helpful for accurate diagnosis and typing of adult onset T1D and provides a brand new diagnosis and treatment target for the adult onset T1D.

The invention relates to the technical field of biological medicines, in particular to application of MiR-30e-5p in diagnosis and treatment of pulmonary arterial hypertension of broilers. A chick embryo hypoxia model and a PASMCs hypoxia model are constructed, the effects of miR-30e-5p on proliferation, migration and phenotypic transformation of PASMCs are systematically researched, and the result shows that the expression of miR-30e-5p can be up-regulated by hypoxia, the proliferation, migration activity and phenotypic transformation capacity of hypoxia-induced PASMCs can be remarkably reduced by knocking down miR-30e-5p in vivo and in vitro, pulmonary artery remodeling is inhibited, and the hypoxia-induced PASMCs can be used for treating pulmonary artery remodeling. A new diagnosis and treatment target is provided for effectively preventing and treating the pulmonary hypertension of the broilers, and a new thought is provided for diagnosis and treatment target screening and drug research and development of the pulmonary hypertension of the broilers.

The invention belongs to the field of molecular biology, and relates to a probe composition for detecting synovial sarcoma SS18-SSX fusion genes as well as a preparation method and application of the probe composition. The invention provides a probe composition for detecting synovial sarcoma SS18-SSX fusion genes, which comprises an SS18 gene 5'probe group, an SS18 gene 3 'probe group, an SSX1 gene 3' probe group and an SSX4 gene 3 'probe group, and the four probe groups are respectively marked by adopting fluorescence of four different colors. When the probe composition is used for synovial sarcoma diagnosis, different SS18-SSX fusion genes can be distinguished in one step according to signal types, a fusion probe does not need to be designed for second-step verification on the basis of SS18 breakage, pathogenesis can be elaborated and prognosis can be judged according to different fusion types, and the method has the advantages of high specificity, high sensitivity and high accuracy. The probe composition and the detection method provided by the invention provide a new diagnosis and prognosis way for clinical diagnosis of synovial sarcoma, and have very high application value.

The invention belongs to the field of biological medicine, and relates to a marker for early diagnosis of Alzheimer's disease and application thereof. In particular discloses a marker for early diagnosis of the Alzheimer's disease, the marker is a Maf1 gene or a protein thereof, and when the Maf1 gene or the protein thereof is highly expressed in neuronal cells, a testee is a crowd with high incidence of the Alzheimer's disease. The invention provides a new diagnosis and treatment target for AD.

The embodiment of the present application provides a method for screening patients in clinical research and a corresponding device, including: obtaining a changed patient set consisting of patients whose diagnosis and treatment information has changed, and obtaining an enrolled patient set consisting of patients belonging to at least one scientific research project; taking patients included in both the changed patient set and the enrolled patient set as target patients, and obtaining newly added diagnosis and treatment data of the target patients; based on the enrollment conditions and newly added diagnosis and treatment data of each scientific research project to which the target patient belongs, determining whether the patient data of the target patient needs to be excluded from the scientific research project. In this solution, only partial data of some patients need to be screened. Compared with full screening, the screening speed is faster and the enrolled patients who do not meet the enrollment requirements can be excluded in time.

The application provides an electrochemical immunosensor for detecting mycobacterium tuberculosis antigen ESAT-6. 60 The application prepares a composite material MXene / C 60 NPs / Au@Pt, and a large number of ESAT-6 aptamers Apt2 are loaded through the bonding of metal particles and amino groups, and finally form a MXene / C 60 NPs / Au@Pt / Apt2 signal probe solution, which effectively amplifies the electrochemical signal. The introduction of gold nanoparticle loaded MoS2 (MoS2-AuNPs) can promote electron transfer, and the density of ESAT-6 aptamer Apt1 on the electrode is increased by using the biotin avidin system, and a novel electrochemical aptamer biosensor based on double signal output is successfully constructed for the detection of ESAT-6 in a typical sandwich form, which provides a new diagnosis approach for the early diagnosis of tuberculosis patients.

The invention discloses a medical follow-up visit management method and device, electronic equipment and a storage medium. The method comprises the following steps: acquiring newest inquiry channel information and newest diagnosis and treatment information of a patient; determining follow-up visit planning information of the patient according to the latest inquiry channel information and the latest diagnosis and treatment information; and generating a follow-up visit template for performing medical follow-up visit on the patient based on the follow-up visit planning information. By adopting the method provided by the invention, the availability of follow-up visit data can be improved.